EPA:ABVX.PA 10 December 2025 - 12 January 2026

Abivax shares jumped 22% to 120.60 euros Monday after French outlet La Lettre reported Eli Lilly is preparing a 15 billion euro takeover bid. CEO Marc de Garidel dismissed the rumors, saying the company is focused on drug development. Neither Abivax nor Lilly commented. Investors await statements at the JPMorgan Healthcare Conference this week.

Abivax shares fell 9.49% to 99.20 euros in Paris on Thursday, reversing a 6% gain from the previous day. Volume reached about 246,000 shares amid anticipation of Phase 3 trial results for obefazimod in late Q2 2026. A U.S. Form 144 filing showed Sofinnova Crossover I SLP intends to sell up to 1,000,000 ADS. BTIG raised its price target on Abivax to $150 and maintained a “Buy” rating.